$Ocuphire Pharma (OCUP.US)$ The third clinical trial of a ne...

The third clinical trial of a new drug under development will begin in early April

The target drug is an oral drug that prevents symptoms in the early stages from diabetes to blindness, and 18 million patients are expected in the United States alone.

As expected, it is an obese powerhouse

The third clinical trial is about 4 to 10 months, and until approval is successfully obtained, it is a stock that cannot be expected to rise except for fluctuations due to speculation.

Since the market size is large, it is a drug that you will continue to take for the rest of your life, so if approval is successfully obtained and it is not acquired, it will become a big monster.